Charles River Laboratories (CRL) : Fox Run Management L.l.c. reduced its stake in Charles River Laboratories by 3.26% during the most recent quarter end. The investment management company now holds a total of 8,900 shares of Charles River Laboratories which is valued at $726,418 after selling 300 shares in Charles River Laboratories , the firm said in a disclosure report filed with the SEC on Oct 12, 2016.Charles River Laboratories makes up approximately 0.44% of Fox Run Management L.l.c.’s portfolio.
Other Hedge Funds, Including , Nisa Investment Advisors boosted its stake in CRL in the latest quarter, The investment management firm added 8,600 additional shares and now holds a total of 17,900 shares of Charles River Laboratories which is valued at $1,460,998. Charles River Laboratories makes up approx 0.02% of Nisa Investment Advisors’s portfolio.Oregon Public Employees Retirement Fund boosted its stake in CRL in the latest quarter, The investment management firm added 475 additional shares and now holds a total of 16,246 shares of Charles River Laboratories which is valued at $1,356,216. Charles River Laboratories makes up approx 0.03% of Oregon Public Employees Retirement Fund’s portfolio. Cutler Group Lp sold out all of its stake in CRL during the most recent quarter. The investment firm sold 1,654 shares of CRL which is valued $138,076. Washington Trust Bank added CRL to its portfolio by purchasing 36 company shares during the most recent quarter which is valued at $2,987.Eqis Capital Management boosted its stake in CRL in the latest quarter, The investment management firm added 98 additional shares and now holds a total of 3,485 shares of Charles River Laboratories which is valued at $289,150. Charles River Laboratories makes up approx 0.02% of Eqis Capital Management’s portfolio.
Charles River Laboratories closed down -1.86 points or -2.23% at $81.62 with 2,37,753 shares getting traded on Tuesday. Post opening the session at $82.94, the shares hit an intraday low of $81.08 and an intraday high of $82.96 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Charles River Laboratories reported $1.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $1.10. The company had revenue of $434.10 million for the quarter, compared to analysts expectations of $424.98 million. The company’s revenue was up 27.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.96 EPS.
Many Wall Street Analysts have commented on Charles River Laboratories. Shares were Downgraded by UBS on Sep 6, 2016 to ” Sell” and Lowered the Price Target to $ 78 from a previous price target of $83 .
Charles River Laboratories International Inc. is a full service early stage contract research company. The Company offers research models for the research and development of new drugs devices and therapies. It develops a portfolio of discovery and safety assessment services both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS) which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA) which provides services that enables the clients to outsource their drug discovery research critical regulatory-required safety assessment testing and related drug discovery and development activities and Manufacturing Support (Manufacturing) which is involved in the production and release of products manufactured by the clients.